Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer
保安醫療與安心治療宣佈合作開發保安 360 CDx 和瓜達 360 組織下一個作為治療陽性非小細胞肺癌的伴侶診斷
Collaboration is Guardant Health's first to explore both tissue- and blood-based assays as companion diagnostics (CDx). Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
協作是Guardant Health第一個探索組織和血液分析作為伴隨診斷(CDX)的公司。̂Taletrectinib是一種研究中的ROS1I抑制劑,用於治療晚期或轉移性ROS1陽性非小細胞肺癌(NSCLC)。